STELARA® STARTS UPSTREAM IN THETHE INFLAMMATORY CASCADE
ACTIVATED
INFLAMMATORY CASCADE
DISRUPTING THE ACTIVATION OF
THE INFLAMMATORY CASCADE
STELARA® is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-23 and IL-12cytokines1,2
IL-23 and IL-12 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cellactivation and CD4+ T-cell differentiation and activation2
In in vitro models, STELARA® was shown to disrupt IL-23 and IL-12mediated signaling and cytokine cascades by disrupting theinteraction of these cytokines with a shared cell-surface receptorchain, IL-12Rβ12
By targeting the upstream regulatory cytokines IL-23 and IL-12,STELARA® was shown to disrupt the resultant inflammatorycascade2
The clinical significance of these characteristics is not fullyknown
References: 1. McInnes IB, Kavanaugh A, Gottlieb AB, et al; for the PSUMMIT I Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3 multicentre, double-blind, placebo-controlled PSUMMIT trial. Lancet. 2013;382(9894):780-789. 2. STELARA® [Prescribing Information]. Horsham, PA: Janssen Pharmaceuticals, Inc.